Figure 7.
Mechanism of action of cabozantinib (XL184). Cabozantinib is a receptor tyrosine kinase (RTK) inhibitor that counteracts the effect of MET, thereby allowing myogenic differentiation. Created with BioRender.com, accessed on 12 July 2023.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.